A new report in Science Translational Medicine explores the root of the high clinical trial failure rate for new cancer drugs. Using CRISPR-Cas9 technology, researchers explored whether drugs still had effects if the purported targets were genetically deleted, finding that the hypothetical mechanisms of action for many investigational drugs were incorrect. With the high costs of clinical trials even in the best of circumstances, Yourway supports any new ways of thinking that may eliminate sources of error that may doom trials from the start.